Bakkus M H, Juge-Morineau N, van der Werff ten Bosch J E
Department of Hematology-Immunology, Medical School, Vrije Universiteit Brussel, Belgium.
Med Oncol. 1996 Jun;13(2):121-31. doi: 10.1007/BF02993863.
The importance of minimal residual disease detection has increased due to the advanced therapeutic protocols available for multiple myeloma and acute leukaemia. High-dose chemotherapy, followed by stem cell transplantation is often used in patients with multiple myeloma. But despite a longer disease-free period and overall survival, all patients relapse. In the treatment of acute leukaemia, there are similar problems. The present strategy is to give continuous chemotherapy to eradicate minimal residual disease. In this review, we consider the methods used to detect and quantify minimal residual disease. At present, the most effective seem to be those based on the use of polymerase chain reactions to detect the malignant cells.
由于针对多发性骨髓瘤和急性白血病有先进的治疗方案，微小残留病检测的重要性日益增加。多发性骨髓瘤患者常采用大剂量化疗，随后进行干细胞移植。但尽管无病生存期和总生存期延长，所有患者都会复发。在急性白血病的治疗中也存在类似问题。目前的策略是给予持续化疗以根除微小残留病。在本综述中，我们考虑了用于检测和量化微小残留病的方法。目前，最有效的方法似乎是基于使用聚合酶链反应来检测恶性细胞的那些方法。
